OVERVIEW
The market for bioburden testing is expected to reach USD 1.34 billion by 2024, continuing to grow over the forecast period at a CAGR of 12%. The market is witnessing growth due to factors such as growth in the medical devices, pharmaceutical and biotechnology industries, rising safety concerns related to food and beverage products, and the growing number of product recalls due to microbial contamination is expected to drive the growth of this market.